Grifols family, Brookfield eye $6 bln takeover bid for Grifols, report says
MADRID, July 8 (Reuters) -The Grifols family and Canadian fund Brookfield are in talks to launch a takeover bid for Spanish drugmaker Grifols GRLS.MC that could be worth around 5.5 billion euros ($5.95 billion), business newspaper Cinco Dias reported on Sunday, citing unnamed people familiar with the plans.
According to the report, Grifols' board held an extraordinary meeting over the weekend to study a preliminary offer presented by the founding family, which currently controls about 30% of the company's shares.
The family's aim is to gain access to the company's books in order to make a final offer in the coming weeks, the report said, adding that Lazard was the sole financial advisor to both parties.
Neither Grifols nor Brookfield were immediately available for comment on Monday.
The company's main shareholders - after the descendants of three brothers who took the company from a small family-owned laboratory in Barcelona to a global player in the plasma derivatives business - include the funds Capital, Blackrock, Europacific and Rokos Global.
Since early January, short-seller fund Gotham City Research has released several reports accusing Grifols of overstating earnings and understating debt. The firm's market value has shed several billion euros since then.
Following Gotham City's reports, Grifols announced governance changes and revised its reported leverage higher after market supervisor CNMV required that it change its calculations.
Last week, Grifols appointed Rahul Srinivasan as chief financial officer in a management reshuffle and Scranton Enterprises, an entity tied to the Grifols family, reached an agreement with a private investor to refinance 377 million euros of debt in one of its units.
($1 = 0.9240 euros)
Reporting by David Latona; Editing by
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
